Rheumatoid arthritis
Conditions
Interventions
None listed
Sponsors
Katayama Orthopadic Rheumatology Clinic
Chondrex Inc. Asama-chemical Co. Ltd. Seien Drugs Compounding Co. Ltd
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Three groups of RA patients of each consisting of 20 and more persons will be studied for at least 6 months. A group ofhealthy persons will be addopted as a control. 1) Untreated RA patients, before and after treatment with DMARDs. 2) RA patients during treatment with DMARs. 3) DMARDs resistant RA patient, before and after treatement with biologicals. 4) Normal adults
Exclusion criteria
Exclusion criteria: RA patients having complication other than rheumatoid arthritis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| a) Therapeutic effects of DMARDs and biologicals will be evaluated by EULAR and ACR criteria. b) Antibody response to E. coli and LPS will be assayed to determine intestinal immune function of individual pateints, whereas serum LPS levels will be determined to measure intestinal barrier function. In addition, serum TNF, IL-6 and anti-CCP antibody levels will be assayed to study the potential linkage between intestinal immune function and inflamation. c) Effect of RMARDs and biologicals on intestinal immune function will be evaluated in individual patients for a 6-month period as well as for their their therapeutic effect. | — |
Secondary
| Measure | Time frame |
|---|---|
| This study will provide basic data to study a new concept that lowered immune function may be the fundamental common disorder in autoimmune diseases. | — |
Countries
Japan
Contacts
Public ContactKou Katayama
Katayama Orthopedic Rheumatology Clinic Department of orthopedic surgery
Outcome results
None listed